Watch ENTA. Know when insiders buy.
One email the day a filing lands. Free.
ENTA
ENANTA PHARMACEUTICALS INC
12.96
+0.26 +2.05%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · shorts 41
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $377.5MP/E —DIV YIELD —FCF YIELD -9.79%REV TTM $65.3M +0.7%NET INCOME −$63.2MNET CASH —52W 7.17 – 16.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | $14.4M | −21.6% | — | −$17.2M | −$19.5M | — | -0.67 | −$10M | $7K | −$10M | Aug 12 |
| Q2 2026 · Mar 31 | $17.2M | +15.0% | — | −$11.9M | −$13.1M | — | -0.45 | −$7.2M | $15K | −$7.2M | Aug 12 |
| Q1 2026 · Dec 31 | $18.6M | +9.8% | — | −$11.3M | −$11.9M | — | -0.42 | −$11.7M | $143K | −$11.8M | Aug 12 |
| Q4 2025 · Sep 30derived | $15.1M | +3.5% | — | −$18.4M | −$18.7M | — | -0.88 | −$6.5M | $1.5M | −$7.9M | Aug 12 |
| Q3 2025 · Jun 30 | $18.3M | +1.9% | — | −$18.9M | −$18.3M | — | -0.85 | $17.5M | $155K | $17.4M | Aug 12 |
| Q2 2025 · Mar 31 | $14.9M | −12.5% | — | −$24.5M | −$22.6M | — | -1.06 | −$13.5M | $2.5M | −$16M | Aug 12 |
| Q1 2025 · Dec 31 | $17M | −5.8% | — | −$23.5M | −$22.3M | — | -1.05 | −$16.8M | $8.7M | −$25.5M | Aug 12 |
| Q4 2024 · Sep 30derived | $14.6M | −22.8% | — | −$29.9M | −$28.8M | — | -1.36 | −$10.4M | $9M | −$19.4M | Nov 19 |
| Q3 2024 · Jun 30 | $18M | — | — | −$24.2M | −$22.7M | — | -1.07 | −$14.8M | $6.5M | −$21.3M | Aug 13 |
| Q2 2024 · Mar 31 | $17.1M | — | — | −$32.8M | −$31.2M | — | -1.47 | −$28.6M | $1.7M | −$30.3M | Aug 13 |
| Q1 2024 · Dec 31 | $18M | — | — | −$34.9M | −$33.4M | — | -1.58 | −$25M | $787K | −$25.8M | Aug 13 |
| Q4 2023 · Sep 30derived | $18.9M | — | — | −$31M | −$28.1M | — | -1.33 | −$21.6M | $1.4M | −$23M | Nov 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | $65.3M | — | −$85.3M | −$81.9M | -125.4% | -3.84 | −$19.3M | $12.9M | −$32.2M | — | — |
| FY2024 · to Sep 30 | $67.6M | — | −$121.7M | −$116M | -171.6% | -5.48 | −$78.8M | $17.9M | −$96.7M | — | — |
| FY2023 · to Sep 30 | $79.2M | — | −$137.2M | −$133.8M | -169.0% | -6.38 | −$103.2M | $9.1M | −$112.2M | — | — |
| FY2022 · to Sep 30 | $86.2M | — | −$123.8M | −$121.8M | -141.3% | -5.91 | −$84.8M | $2.1M | −$86.9M | — | — |
| FY2021 · to Sep 30 | $97.1M | — | −$109.6M | −$79M | -81.4% | -3.92 | −$70M | $750K | −$70.7M | — | — |
| FY2020 · to Sep 30 | $122.5M | — | −$41.6M | −$36.2M | -29.5% | -1.81 | $7.1M | $1.4M | $5.6M | — | — |
Every number comes from ENANTA PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.